First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W-pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; W pro1 (Primary) ; Goserelin
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms PRO-MERIT
Sponsors BioNTech

Most Recent Events

20 Mar 2024 This trial has been Discontinued in Hungary and Germany according to European Clinical Trials Database record.
14 Mar 2024 Status changed from active, no longer recruiting to discontinued.
24 Oct 2023 Planned End Date changed from 1 Jul 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight